BIOMAT Database Logo BIOMAT Database Logo

Naltrexone attenuates self-injurious behavior in mentally retarded subjects. 1990

H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
Institute for Mental Retardation, Eemeroord, Baarn, The Netherlands.

The effect of naltrexone on the frequency of self-injurious behavior (SIB) was investigated in 6 male subjects with profound mental retardation. Following a double-blind placebo-controlled crossover design, naltrexone was administered in a dose of 50 mg once daily for 3 consecutive weeks. In 2 of 5 subjects, a significant decrease of SIB frequency could be demonstrated, and in 1, a tendency to a reduction was found. No effect on duration of restrain time was found in 3 subjects. These data suggest that disturbances of the endogenous opioid systems may be involved in the pathophysiology of SIB of certain patients.

UI MeSH Term Description Entries
D007326 Institutionalization The caring for individuals in institutions and their adaptation to routines characteristic of the institutional environment, and/or their loss of adaptation to life outside the institution. Institutionalized Persons,Institutionalizations,Institutionalized Person,Person, Institutionalized,Persons, Institutionalized
D008297 Male Males
D008607 Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28) Disability, Intellectual,Idiocy,Mental Retardation,Retardation, Mental,Deficiency, Mental,Intellectual Development Disorder,Mental Deficiency,Mental Retardation, Psychosocial,Deficiencies, Mental,Development Disorder, Intellectual,Development Disorders, Intellectual,Disabilities, Intellectual,Disorder, Intellectual Development,Disorders, Intellectual Development,Intellectual Development Disorders,Intellectual Disabilities,Mental Deficiencies,Mental Retardations, Psychosocial,Psychosocial Mental Retardation,Psychosocial Mental Retardations,Retardation, Psychosocial Mental,Retardations, Psychosocial Mental
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004314 Down Syndrome A chromosome disorder associated either with an extra CHROMOSOME 21 or an effective TRISOMY for chromosome 21. Clinical manifestations include HYPOTONIA, short stature, BRACHYCEPHALY, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, single transverse palmar crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213) Mongolism,Trisomy 21,47,XX,+21,47,XY,+21,Down Syndrome, Partial Trisomy 21,Down's Syndrome,Partial Trisomy 21 Down Syndrome,Trisomy 21, Meiotic Nondisjunction,Trisomy 21, Mitotic Nondisjunction,Trisomy G,Downs Syndrome,Syndrome, Down,Syndrome, Down's
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
Stress and self-injurious behavior; hormonal and serotonergic parameters in mentally retarded subjects.
January 1999, Pharmacopsychiatry,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
Psychopharmacology of self-injurious behavior in the mentally retarded.
May 1987, Journal of the American Academy of Child and Adolescent Psychiatry,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
[Psychopharmacological therapy of self-injurious behavior in mentally retarded individuals].
November 1999, Der Nervenarzt,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
Fluoxetine treatment of self-injurious behavior in mentally retarded patients.
August 1990, Journal of clinical psychopharmacology,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
Pharmacological treatment of self-injurious behavior in mentally retarded persons.
September 1985, Journal of autism and developmental disorders,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior.
July 1990, American journal of mental retardation : AJMR,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
Self-injurious behavior and stereotypy in an institutionalized mentally retarded population.
January 1984, Applied research in mental retardation,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
The differential diagnosis of self-injurious behavior in mentally retarded people.
January 1989, Psychopharmacology bulletin,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
Naltrexone decreases self-injurious behavior.
October 1987, Annals of neurology,
H Kars, and W Broekema, and I Glaudemans-van Gelderen, and W M Verhoeven, and J M van Ree
Opiate antagonists for recurrent self-injurious behavior in three mentally retarded adults.
May 1995, Psychiatric services (Washington, D.C.),
Copied contents to your clipboard!